drugset / Trial / NCT03663101
Dysport in Post-Surgical Neuralgia
RandomizedParallel-groupDouble-blindTreatment
Summary
The study is designed to determine whether a currently licensed version of botulinum toxin (Dysport®) is effective for the treatment of pain that has developed and/or persisted for months or years around the scar of a previous surgical site, and whether this condition could be suitable for the testing of similar new medicines. The study will compare three different doses of Dysport® to see if there is benefit and/or a best dose for treating persistent post-surgery scar pain.
Timeline
- Start
- 2018-10-30
- Primary completion
- 2019-11-08
- Completion
- 2019-11-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 0.2 ml | Other |
| Background | Lidocaine | Other / unclassified | 2.5 mg | Subcutaneous |